000153436 001__ 153436
000153436 005__ 20240229123043.0
000153436 0247_ $$2doi$$a10.1111/ene.14159
000153436 0247_ $$2pmid$$apmid:31994783
000153436 0247_ $$2ISSN$$a1351-5101
000153436 0247_ $$2ISSN$$a1468-1331
000153436 0247_ $$2ISSN$$a1471-0552
000153436 0247_ $$2altmetric$$aaltmetric:77409475
000153436 037__ $$aDKFZ-2020-00287
000153436 041__ $$aeng
000153436 082__ $$a610
000153436 1001_ $$aBerberich, Anne$$b0
000153436 245__ $$aRisk factors associated with progressive lacunar strokes and benefit from dual anti-platelet therapy.
000153436 260__ $$aOxford$$bBlackwell Science65503$$c2020
000153436 264_1 $$2Crossref$$3online$$bWiley$$c2020-02-18
000153436 264_1 $$2Crossref$$3print$$bWiley$$c2020-05-01
000153436 264_1 $$2Crossref$$3print$$bWiley$$c2020-05-01
000153436 3367_ $$2DRIVER$$aarticle
000153436 3367_ $$2DataCite$$aOutput Types/Journal article
000153436 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1597744147_9638
000153436 3367_ $$2BibTeX$$aARTICLE
000153436 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153436 3367_ $$00$$2EndNote$$aJournal Article
000153436 500__ $$a2020 May;27(5):817-824
000153436 520__ $$aEarly neurological deterioration (END) occurs in 20-30% of patients with lacunar stroke and challenges their clinical management. This retrospective cohort study analyzed clinical and neuroimaging risk factors predicting the occurrence of END, the functional outcome after END and potential benefit from dual anti-platelet therapy (DAPT) in patients with lacunar strokes.Factors associated with END and benefit from DAPT were retrospectively analyzed in 308 patients with lacunar stroke symptoms and detected lacunar infarction by MRI. END was defined by deterioration of ≥3 total NIHSS points, ≥2 NIHSS points for limb paresis or documented deterioration within five days after admission. Patients were treated with DAPT according to in-house standards. Primary efficacy endpoint for functional outcome was fulfilled if NIHSS at discharge improved after END at least to the score at admission.Male gender (OR=2.08; 95%CI 1.09-4.00), higher age (OR=1.65 per 10 years; 95%CI 1.18-2.31), motor paresis (OR=18.89, 95%CI 4.66-76.57) and infarction of the internal capsule or basal ganglia (OR=3.58, 95%CI 1.26-10.14) were associated with an increased risk for END. Larger diameter of infarction (OR=0.85, 95%CI 0.76-0.95), more microangiopathic lesions (OR=0.75, 95%CI 0.57-0.99) and pontine localization (OR=0.29, 95%CI 0.12-0.65) were factors associated with unfavorable functional outcome after END occurred. Localization in the internal capsule or basal ganglia was identified as significant predictive factor for a benefit from DAPT after END.Identified clinical and neuroimaging factors predicting END occurrence, functional outcome after END and potential benefit from DAPT might improve the clinical management of patients with lacunar strokes.
000153436 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153436 542__ $$2Crossref$$i2020-02-18$$uhttp://creativecommons.org/licenses/by-nc/4.0/
000153436 542__ $$2Crossref$$i2020-02-18$$uhttp://doi.wiley.com/10.1002/tdm_license_1.1
000153436 588__ $$aDataset connected to CrossRef, PubMed,
000153436 7001_ $$aSchneider, Christine$$b1
000153436 7001_ $$aHerweh, Christian$$b2
000153436 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b3$$udkfz
000153436 7001_ $$aReiff, Tilman$$b4
000153436 7001_ $$aBendszus, Martin$$b5
000153436 7001_ $$aGumbinger, Christoph$$b6
000153436 7001_ $$aRingleb, Peter$$b7
000153436 77318 $$2Crossref$$3journal-article$$a10.1111/ene.14159$$bWiley$$d2020-02-18$$n5$$p817-824$$tEuropean Journal of Neurology$$v27$$x1351-5101$$y2020
000153436 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.14159$$gp. ene.14159$$n5$$p817-824$$tEuropean journal of neurology$$v27$$x1351-5101$$y2020
000153436 909CO $$ooai:inrepo02.dkfz.de:153436$$pVDB
000153436 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000153436 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153436 9141_ $$y2020
000153436 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153436 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153436 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153436 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2015
000153436 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153436 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153436 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000153436 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153436 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153436 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153436 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153436 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153436 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000153436 980__ $$ajournal
000153436 980__ $$aVDB
000153436 980__ $$aI:(DE-He78)C060-20160331
000153436 980__ $$aUNRESTRICTED
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1747-4949.2012.00789.x
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000144084
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.52.1.29
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jns.2009.08.065
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2176/nmc.35.663
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jns.2011.06.057
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/ane.12961
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1600-0404.1985.tb03208.x
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e318253d62f
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2169/internalmedicine.54.4442
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jns.2011.02.006
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s13760-017-0827-2
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/bmj.k5130
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1056/NEJMoa1800410
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/ijs.12129
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/STROKEAHA.118.023789
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2214/ajr.149.2.351
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/STROKEAHA.113.004562
000153436 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1161/01.STR.32.5.1154